NEW

Private Company Data

Track valuations, funding rounds, and more before IPO.

Biotechnology
Biotech and biopharmaceutical companies engaged in research, discovery, development, and production of innovative drug and drug- related technologies.
Market Cap
682.46B
Industry Weight
10.48%
Companies
666
Employees
140,405
Biotechnology S&P 500 ^GSPC
Loading Chart for Biotechnology

Day Return

Industry
2.01%
S&P 500
1.97%

YTD Return

Industry
2.51%
S&P 500
5.52%

1-Year Return

Industry
12.03%
S&P 500
6.33%

3-Year Return

Industry
1.35%
S&P 500
22.85%

5-Year Return

Industry
71.16%
S&P 500
115.93%

Note: Industry performance is calculated based on the previous closing price of all industry constituents

Largest Companies in This Industry

View More
Table View
Heatmap View
Name
Last Price
1Y Target Est.
Market Weight
Market Cap
Day Change %
YTD Return
Avg. Analyst Rating
492.69 497.01 20.40% 126.882B -1.96% +22.35%
Buy
637.36 923.05 11.26% 70.039B +0.24% -10.52%
Buy
268.46 311.24 5.57% 34.626B -0.94% +14.09%
Buy
31.37 40.92 2.97% 18.483B -0.88% +22.97%
Buy
20.32 27.80 2.41% 14.985B -1.36% +13.87%
Strong Buy
77.99 95.49 2.24% 13.953B +0.39% +12.96%
Strong Buy
71.44 96.77 2.19% 13.615B -1.91% +8.69%
Buy
31.12 54.22 1.93% 11.976B -3.11% -25.16%
Hold
60.60 74.53 1.88% 11.675B -0.13% -12.26%
Buy
36.70 37.06 1.69% 10.481B -0.38% +10.21%
Buy

Investing in the Biotechnology Industry

Start Investing in Biotechnology Through These Companies

Top Performing Companies

View More
Name
Last Price
1Y Target Est.
YTD Return
9.48 15.83 +305.13%
8.50 8.54 +144.25%
28.10 42.50 +134.17%
5.64 15.33 +126.51%
10.46 18.60 +93.35%

High Growth Companies

View More
Name
Last Price
Growth Estimate
YTD Return
183.92 +605.13% +17.40%
22.39 +396.54% -16.70%
15.95 +256.00% -10.39%
11.58 +222.00% -31.76%
22.21 +174.42% -10.44%

Biotechnology Research

View More

Discover the Latest Analyst and Technical Research for This Industry

  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, a look at Fortive shares ahead of spinoff; generative AI is giving tech landscape a jolt; we see plenty of opportunity in US REITs; and Innovent Biologics, Haier Smart Homes, and Lithium Americas.

     
  • The Argus Mid-Cap Model Portfolio

    Despite bursts of outperformance, small- and mid-cap stocks (SMID) have underperformed large-caps year to date -- as they have over the past five years. But they may be in a better position to generate market-beating returns going forward. For one thing, SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the trade and tariff debate, or fallout from unrest in the Middle East, the Russian invasion of Ukraine, issues in China, or other geopolitical developments. As well, the prices of SMID stocks generally are lower than the prices of large-caps. Finally, there are long stretches in the record books when SMID stocks have outperformed large-caps. SMID stocks can be risky, but despite those risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 20% of the U.S. stock market's capitalization is comprised of SMID stocks.

     
  • Daily – Vickers Top Buyers & Sellers for 03/28/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Insider Picks for 03/28/2025

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

From the Community

Biotechnology News